Accueil » Communiqués de presse » Valbiotis will present significant preclinical results for its active substance TOTUM•448 against fatty liver diseases (NAFL and NASH), at the annual meeting of the American Association for the Study of Liver Diseases (AASLD).
Les communiqués de presse
27Oct2022
Valbiotis will present significant preclinical results for its active substance TOTUM•448 against fatty liver diseases (NAFL and NASH), at the annual meeting of the American Association for the Study of Liver Diseases (AASLD).
We use cookies to guarantee the best experience on our site, to make statistics, to offer you third party services such as video like Youtube, social networks sharing. By clicking on validate and closing this banner, you accept the deposit of cookies.AcceptRefuseMore information
You can revoke your consent at any time by using the "Revoke Consent" button.Revoke consent
